Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Enhertu Goes Into High Gear With HER2-Low Breast Cancer Approval

Aug 05 2022

• By Joseph Haas

FDA Approved — Enhertu use in HER2-low breast cancer may take off with FDA nod

Related Content

ASCO: AstraZeneca's Enhertu Is Poised To Change The Breast Cancer Paradigm

Jun 06 2022

AstraZeneca and Daiichi Sankyo’s Enhertu Eyes 50% Of Breast Cancer Market Following HER2-Low Data

Feb 21 2022

AstraZeneca/Daiichi's Enhertu Expansion Strategy Progresses With New Approval

May 05 2022

Boost For Daiichi's Oncology Ambitions As AZ Agrees Huge $6.9bn Deal For Lead ADC Asset

Mar 29 2019

Related Companies

AstraZeneca PLC

Daiichi Sankyo Co., Ltd.

Additional Topics

Approvals Personalized Medicine Business Strategies Commercial Cancer BioPharmaceutical

More from New Products

More from Scrip

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window